本文源自：金融界 作者：行情君 联康生物科技集团有限公司专注于生物创新药、高值仿制药、医美新原料及CMO四大战略领域的研 发、生产、销售，旨在满足中国对优质医疗保健解决方案的需求。此外，该公司还积极与香江集团等知 名公司进行战略合作，通过战略合作及引入协议授权模式来扩大产品组合，并将继续投入提升产品质量 和供应链安全性，以满足国内老龄化和人口增长趋势带来的医疗需求。 截至2024年年报，联康生物科技集团营业总收入5.12亿元、净利润7665.2万元。 8月12日，联康生物科技集团(00690)盘中下跌5.0%，截至14:59，报0.152元/股，成交1056.67万元。 ...

本文源自：金融界 作者：行情君 8月12日，联康生物科技集团(00690)盘中上涨5.0%，截至14:00，报0.168元/股，成交428.07万元。 联康生物科技集团有限公司专注于生物创新药、高值仿制药、医美新原料及CMO四大战略领域的研 发、生产、销售，旨在满足中国对优质医疗保健解决方案的需求。此外，该公司还积极与香江集团等知 名公司进行战略合作，通过战略合作及引入协议授权模式来扩大产品组合，并将继续投入提升产品质量 和供应链安全性，以满足国内老龄化和人口增长趋势带来的医疗需求。 截至2024年年报，联康生物科技集团营业总收入5.12亿元、净利润7665.2万元。 ...

Group 1 - The core viewpoint of the article highlights the positive market performance of LianKang Biotechnology Group, with a stock price increase of 6.67% to 0.16 CNY per share and a trading volume of 2.55 million CNY as of 11:27 AM on August 4 [1] - LianKang Biotechnology Group focuses on four strategic areas: biopharmaceutical innovation, high-value generic drugs, new materials for medical aesthetics, and CMO (Contract Manufacturing Organization) [1] - The company aims to meet the growing demand for quality healthcare solutions in China, driven by aging population and population growth trends [1] Group 2 - As of the 2024 annual report, LianKang Biotechnology Group reported total revenue of 512 million CNY and a net profit of 76.65 million CNY [2]

8月1日，联康生物科技集团(00690)盘中上涨5.11%，截至10:25，报0.144元/股，成交181.85万元。 截至2024年年报，联康生物科技集团营业总收入5.12亿元、净利润7665.2万元。 本文源自：金融界 作者：行情君 联康生物科技集团有限公司专注于生物创新药、高值仿制药、医美新原料及CMO四大战略领域的研 发、生产、销售，旨在满足中国对优质医疗保健解决方案的需求。此外，该公司还积极与香江集团等知 名公司进行战略合作，通过战略合作及引入协议授权模式来扩大产品组合，并将继续投入提升产品质量 和供应链安全性，以满足国内老龄化和人口增长趋势带来的医疗需求。 ...

Group 1 - The core viewpoint of the news highlights the recent stock performance of Lian Kang Biotechnology Group, which closed at HKD 0.080, down 3.61% from the previous trading day, despite reaching a one-year high of HKD 0.085 during the day [1] - The company experienced a net outflow of HKD 653.26 thousand, with a total inflow of HKD 156.48 thousand and an outflow of HKD 668.904 thousand on the same day [1] Group 2 - Lian Kang Biotechnology Group, established in 2001, focuses on four strategic areas: innovative biopharmaceuticals, high-value generics, new materials for medical aesthetics, and CMO, integrating R&D, production, and sales [2] - The company has a strong management team with decades of international pharmaceutical experience and is well-positioned to benefit from positive changes in the Chinese healthcare market [2] - Lian Kang is committed to improving patient quality of life through innovative therapies, addressing the significant pressure on the domestic healthcare system due to aging population and chronic diseases [2] - The company has made significant operational enhancements, including the establishment of a medical department and market access department, to maintain strong growth momentum [2] - A strategic alliance was formed with Xiangjiang Group, a top 50 private enterprise in China, to promote Lian Kang's products through its healthcare channels [2] - The company emphasizes ethical and responsible business practices, positioning itself as a preferred partner in the healthcare sector [2] - Lian Kang is focused on ensuring supply chain security and accountability, aligning with the latest government policies [2] - The company’s production facilities are equipped with advanced technology and have received cGMP certification, establishing it as a high-quality pharmaceutical supplier [2] - Lian Kang aims to become a leader in chronic disease management by providing innovative health products and treatment solutions in China [2]